November 5, 2020
This article was originally posted on Docwire News. DocWire News sat down with Saad Usmani, M.D., MBA, FACP to discuss an indirect treatment comparison study which assesses DARZALEX® (daratumumab) Plus Lenalidomide and Dexamethasone (D-Rd) and Bortezomib-Containing Regimens in Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma. To continue reading this article on Docwire News.
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand